Amgen (NASDAQ: AMGN) director granted 665-share equity award, now holds 18,284
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Jacks Tyler reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. director Tyler Jacks reported a compensation-related equity grant rather than an open-market trade. He received 665 shares of common stock via immediately vesting Restricted Stock Units under Amgen’s 2009 Director Incentive Program. After this award, he directly holds 18,284 common shares, including 2,975 dividend equivalents tied to unvested RSUs that will be paid in stock as they vest.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Jacks Tyler
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 665 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 18,284 shares (Direct, null)
Footnotes (1)
- The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule. These shares include 2,975 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
Key Figures
RSU grant: 665 shares
Post-transaction holdings: 18,284 shares
Dividend equivalents: 2,975 DEs
+1 more
4 metrics
RSU grant
665 shares
Common stock received via immediately vesting RSUs on May 19, 2026
Post-transaction holdings
18,284 shares
Total Amgen common stock directly held after the grant
Dividend equivalents
2,975 DEs
DEs credited to unvested RSUs, payable in common stock
Grant price
$0.00 per share
Indicates a compensation award, not a market purchase
Key Terms
Restricted Stock Units (RSUs), Amgen Inc. 2009 Director Incentive Program, Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan, dividend equivalents (DEs), +1 more
5 terms
Restricted Stock Units (RSUs) financial
"The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program..."
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
Amgen Inc. 2009 Director Incentive Program financial
"RSUs were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended..."
Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan financial
"granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan..."
dividend equivalents (DEs) financial
"These shares include 2,975 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan..."
dividend reinvestment plan financial
"2,975 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan."
A dividend reinvestment plan lets shareholders automatically use cash dividends to buy more shares of the same company instead of receiving the money. It matters to investors because it turns regular payouts into a steady way to grow ownership and take advantage of compound returns—like having your savings automatically buy additional slices of a pie over time—while often reducing transaction costs and smoothing purchase timing.
FAQ
What did Amgen (AMGN) director Tyler Jacks report in this Form 4?
Tyler Jacks reported receiving 665 shares of Amgen common stock through an immediately vesting Restricted Stock Unit grant. This is a compensation-related award, not an open-market stock purchase or sale, and reflects standard director equity compensation under Amgen’s incentive programs.
Was Tyler Jacks’ Amgen (AMGN) Form 4 transaction a stock purchase or sale?
The filing shows a grant of 665 shares at a price of $0.00 per share, coded as an award acquisition. This indicates a compensation-related grant of Restricted Stock Units, not an open-market purchase or sale initiated by the director on a stock exchange.
What are the key terms of Tyler Jacks’ Amgen (AMGN) RSU grant?
The Restricted Stock Units were granted under Amgen’s 2009 Director Incentive Program and vested immediately. Each vested RSU is paid in one share of Amgen common stock, and directors may defer payment so shares are delivered later according to an elected deferral schedule.
What do the 2,975 DEs reported in the Amgen (AMGN) Form 4 represent?
The 2,975 DEs are dividend equivalents credited on unvested RSUs under Amgen’s equity incentive plan. They are paid out in Amgen common shares on a one-to-one basis when the associated RSUs vest, plus a cash payment for any remaining fractional share amount.
Does this Amgen (AMGN) Form 4 indicate any remaining derivative positions for Tyler Jacks?
The derivative section of the filing is empty, indicating no derivative securities such as stock options or similar instruments are reported as remaining positions in this Form 4. The disclosure focuses on common stock held directly and equity granted through RSUs and dividend equivalents.